IMJUDO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Romania, UK.

Active ingredients

The drug IMJUDO contains one active pharmaceutical ingredient (API):

1	Tremelimumab UNII QEN1X95CIX - TREMELIMUMAB
	Tremelimumab is a selective, fully human IgG2 antibody that blocks CTLA-4 interaction with CD80 and CD86, thus enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced antitumour activity. Cytotoxic T lymphocyte-associated antigen (CTLA-4) is primarily expressed on the surface of T lymphocytes.
	Read more about Tremelimumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMJUDO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX20		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3038565, 3038576
FR	Base de données publique des médicaments	68577115
IT	Agenzia del Farmaco	050595014, 050595026
JP	医薬品医療機器総合機構	4291465A1020, 4291465A2026
LT	Valstybinė vaistų kontrolės tarnyba	1096578, 1096579
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69596001, W69596002
US	FDA, National Drug Code	0310-4505, 0310-4535